Exemestane for primary prevention of breast cancer in postmenopausal women

American Journal of Health-System Pharmacy

Volumn 69, Issue 16, 2012, Pages 1384-1388

  Zhang, Yang ^a   Simondsen, Katherine ^b   Kolesar, Jill M ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTHRALGIA; BLEEDING; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CARCINOMA IN SITU; CARDIOVASCULAR DISEASE; CATARACT; DIARRHEA; EDEMA; ENDOMETRIUM CANCER; FATIGUE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HYPERHIDROSIS; INSOMNIA; JOINT STIFFNESS; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; MUSCLE SPASM; NAUSEA; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; VAGINA DISCHARGE; VOMITING; WEIGHT REDUCTION;

EID: 84865993239     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110585     Document Type: Review

References (17)

1. Bevers TB, Armstrong DK, Arun B et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010; 8:1112-46.
2. Cuzick J, DeCensi A, Arun B et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011; 12:496-503.
3. National Cancer Institute. Breast cancer risk assessment tool: about the tool. www.cancer.gov/bcrisktool/about-tool.aspx (accessed 2012 Apr 24).
4. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361:296-300. (Pubitemid 36126189)
5. Visvanathan K, Chlebowski RT, Hurley P et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009; 27:3235-58.
6. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90:1371-88. (Pubitemid 28439961)
7. Vogel VG, Costantino JP, Wickerham DL et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res. 2010; 3:696-706.
8. Cummings SR, Ensrud K, Delmas PD et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010; 362:686-96.
9. Cummings SR, McClung M, Reginster JY et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011; 26:397-404.
10. Aromasin (exemestane) prescribing information. New York: Pfizer; 2011 Apr.
11. Goss PE, Ingle JN, Ales-Martinez JE et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011; 364:2381-91.
12. Hadji P, Asmar L, van Nes JG et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium substudies. J Cancer Res Clin Oncol. 2011; 137:1015-25.
13. ClinicalTrials.gov. Studies related to aromatase inhibitor therapy in osteoporosis. www.clinicaltrials.gov/ct2/results?term= aromatase+inhibitor+therapy+in+osteoporosis (accessed 2012 Jun 14).
14. National Comprehensive Cancer Network. Breast cancer risk reduction: NCCN clinical practice guidelines in oncology, version 3.2001. www.nccn.org/ professionals/physician-gls/pdf/breast-risk.pdf (accessed 2011 Dec 9).
15. Vogel VG. Tipping the balance for the primary prevention of breast cancer. J Natl Cancer Inst. 2010; 102:1683-5.
16. Fagerlin A, Zikmund-Fisher BJ, Nair V et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010; 119:613-20.
17. Red book: pharmacy's fundamental reference. 114th ed. Philadelphia: Lippincott Williams & Wilkins; 2010:6816-8.